Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Launch date set for Abraxane for metastatic breast cancer
February 24th, 2005
American Pharmaceutical Partners, Inc., (APPX) announced that February 8, 2005, was the scheduled launch date of Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). Abraxane will be marketed by the national sales force of Abraxis Oncology, APP's proprietary sales and marketing division. "We are excited by the opportunity to provide this new and innovative treatment option for women with advanced breast cancer," said Al Heller, president and CEO of American Pharmaceutical Partners. "Abraxane has unique attributes that may be beneficial to patients and caregivers alike,...
Source: Women's Health Weekly (2005-02-24)
|
